Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.US-based biotechnology company GigaGen has developed a new class of drugs, recombinant hyperimmunes, to potentially treat patients with Covid-19.
Hospitals across the country are using convalescent plasma to treat Covid-19. Obtained from people who recovered from the disease, convalescent plasma contains antibodies that could fight the infection.
However, plasma from many donors has weak antibody levels, limiting the manufacture of high-potency doses required to tackle the Covid-19 pandemic.